A3153235-3128-40AC-9371-AFA1F61E3E59
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 24.14586070959264
- age_years
- 63
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.632
- MYC_TARGETS_V1+0.619
- E2F_TARGETS+0.608
- MYC_TARGETS_V2+0.545
- UNFOLDED_PROTEIN_RESPONSE+0.478
- MITOTIC_SPINDLE+0.460
- NOTCH_SIGNALING+0.392
- DNA_REPAIR+0.364
- MTORC1_SIGNALING+0.347
- TGF_BETA_SIGNALING+0.338
Top 10 suppressed
- KRAS_SIGNALING_DN-0.433
- BILE_ACID_METABOLISM-0.404
- INTERFERON_ALPHA_RESPONSE-0.331
- INFLAMMATORY_RESPONSE-0.259
- INTERFERON_GAMMA_RESPONSE-0.244
- COAGULATION-0.233
- MYOGENESIS-0.230
- HEME_METABOLISM-0.188
- XENOBIOTIC_METABOLISM-0.187
- APICAL_SURFACE-0.177
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DD5AA3F8-E3EE-4EDD-8152-B1CC07B70A08 | — | — | 0.945 |
| 2 | 93123F83-44EC-4480-9453-F061AA7BC2DB | — | — | 0.915 |
| 3 | SRR934873 | — | — | 0.912 |
| 4 | 98D004A9-E3F0-448E-BFE2-359F25DF356C | — | — | 0.902 |
| 5 | ERR2598051 | fetal | fetal | 0.892 |
| 6 | SRR934893 | — | — | 0.886 |
| 7 | SRR934748 | — | — | 0.886 |
| 8 | 67719D37-8CC2-42B5-AF44-6D5AC258FDB1 | — | — | 0.885 |
| 9 | SRR934890 | — | — | 0.884 |
| 10 | 9970B75F-7AC6-431B-BDBB-120D01582CBE | — | — | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.632 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.619 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.608 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.545 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.478 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.460 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.392 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.364 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.347 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.338 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.285 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.276 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.266 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.261 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.235 | Inavolisib | — uncovered |
| HYPOXIA | 0.201 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.187 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.186 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.148 | Remibrutinib | — uncovered |